ABOUT THE EVENT
CAR-T therapy is set to revolutionize oncology pipelines and mark a new era for personalized medicine. With the recent approvals of Yescarta and Kymriah and the $11 billion acquisition of Kite, the race is on to lead the commercialization of safe, efficacious and accessible CAR-T therapy.
The fourth annual CAR-T congress USA is bringing together the leading pharmaceutical companies, the disruptive biotechs, and pioneering academic institutions to assess emerging novel data and tackle the current challenges including antigen discovery, manufacturing scalability, and efficacy.
Join discussions with Dr. Christina Coughlin and Dr. Leonard Lichtenfeld to determine how we avoid cheaper and more potent biologics hindering the progress of CAR-T, how we effectively edit T cells at scale, and how the industry is pushing for patient access to accelerate your CAR-T pipelines.
Discover first-hand the novel research being done by one of the leading ‘biotechs to watch’ Tmunity, as we explore the potential of CAR-T switches to control and manage CAR-T therapy effectively. Join Fate Therapeutics, TCR2 and Cellectis to determine how novel CAR-T constructs and gene editing technology are paving the way for the next generation CAR-Ts.
With two tracks for preclinical discovery and clinical development, refine your methods from optimizing T cell phenotypes and longevity to providing quality control for robust manufacturing. With sessions ran by Gilead and Legend Biotech on strengthening the business strategy for CAR-T and global regulation sessions ran by the EMA, this is your chance to be informed when commercializing your CAR-T therapy.
Be part of the movement that engineers a strategy to reprogram the cancer treatments we know today.